Iboga (Tabernanthe iboga)
What Is Iboga?
Iboga is listed botanically as Tabernanthe iboga, a plant of the Apocynaceae family, native to the rainforests of West Central Africa. The material in circulation is root bark — an underground part, harvested once the plant has drawn its reserves down. Most people search for it simply as Iboga; suppliers, pharmacopoeias and interaction databases list it as Tabernanthe iboga, and matching the two is the first step in identifying what is actually in a product. Its character is described as bitter, intensely alkaloidal, which is often how the raw material is checked for quality.
Use of Iboga predates its chemical analysis by a long way: earlier records describe it by season, preparation and the part gathered rather than by any constituent, and that practical knowledge is what later study was measured against. Beyond its practical use it carries cultural associations — bwiti sacrament — 'tree of knowledge' for Gabonese initiation.
Today most searches for Iboga come from people reading about detox, bone health, eye health and weight management, or checking how it sits alongside a medication they already take. The use most often documented in the literature is interrupts opioid and stimulant addiction (single-dose studies), followed by Modulates NMDA, opioid, and serotonergic receptors.
How Does Iboga Work?
Iboga works as a mixture rather than a single isolated compound, and its profile is usually described by the class of constituents present in root bark rather than by one marker molecule.
Traditional practice described Iboga in terms of taste, warmth and preparation rather than molecules — a working vocabulary that predicted which extractions were worth making long before any compound was isolated.
Published research is limited, leaning on small trials, laboratory work and animal models, and this profile cites 1 source. Reported findings centre on davis et al. Where research exists, it examines interrupts opioid and stimulant addiction (single-dose studies), Modulates NMDA, opioid, and serotonergic receptors and long-acting noribogaine metabolite. These are areas of study, not established outcomes, and results differ by preparation and dose.
How the plant is prepared changes what you actually get. Its constituents move readily into alcohol — so a preparation made in another medium will not carry the same fraction of the plant, which is why traditional recipes specify one over another.
The reason Iboga is treated as its own entry rather than a substitute for a related plant is proportion: related species share several of these compound classes, but not in the same ratio or concentration.
Because these constituents are processed by the same pathways that handle many medicines, Iboga is documented as interacting with qt-prolonging drugs, opioids and ssris/snris. That is a question of shared metabolism rather than of potency, and it is the main reason the plant is listed in interaction references at all.
Dose, plant part and growing conditions all shift the constituent profile, so two products carrying the name Iboga can differ substantially; this is why reference entries specify root bark and, where they exist, standardisation markers.